Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To KYPROLIS Label
Amgen announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted...
AstraZeneca reports results from the ARCTIC trial in third-line non-small cell lung cancer
AstraZeneca and MedImmune, its global biologics research and development arm, announced high-level results from the Phase III ARCTIC trial in...
BERG Announces the Dosing of First UK Patient in Phase II Combination Trial of BPM 31510 and Gemcitabine for Patients with Pancreatic Cancer
ERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, announced the dosing of the...
CPhI & P-MEC China 2018: Build lucrative pharma business partnerships in China
Are you looking for new business partners, extendingyour distributor network or sourcing specific products on the Chinese pharma market? We...
More Than 60% of Drug Safety Experts Plan To Use AI to Improve the Speed and Security of Adverse Event Case Processing
New research conducted in partnership with Informa Engage / Pharma Intelligence reveals that 62% of drug safety experts have implemented...
Prothena Announces Global Neuroscience R&D Collaboration with Celgene for Novel Therapies for Patients with Neurodegenerative Diseases
Prothena Corporation plc , a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in...
Roche’s TECENTRIQ plus chemotherapy reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer: Phase III IMpower131 study
Roche announced that the Phase III IMpower131 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the...
Tasigna drug to treat children with rare form of leukemia receives FDA approval: Novartis
Novartis announced that the US FDA expanded the indication for Tasigna (nilotinib) to include treatment of first- and second-line pediatric...
GSK commences phase III study of Benlysta and rituximab combination in systemic lupus erythematosus
GSK announced the start of a phase III study investigating Benlysta (belimumab) in combination with rituximab in adult patients with...
Praluent extensively reduces risk of cardiovascular events in high-risk patients, and was associated with lower death rateÂ
Sanofi and Regeneron Pharmaceuticals, Inc. announced that the ODYSSEY OUTCOMES trial met its primary endpoint, showing Praluent® (alirocumab) significantly reduced the...
Latest News
About Us
Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.